BOSTON, Feb. 10, 2011 /PRNewswire/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company generated revenues during the month of January 2011 in the amount of $34,291.33 versus $32,458.23 for the month of January 2010, which reflects an increase of 5.64%. The revenue for the month of January 2011 is a result of instrument sales to over twenty-five Hospitals, Clinics, Healthcare Centers, Medical Centers and Surgery Centers across the United States.
January sales were primarily driven by the Company's disposable surgical instruments segment. The Company looks towards continued growth in 2011 through new product development, new product sales and the completion of the requirements for the Company's ISO 13485 quality management system (QMS) initiative. The ISO QMS initiative is a major step in obtaining the CE Mark and the permission to sell medical devices in the European Union.
"We are pleased with the results for the month of January considering Solos, as well as most of the nation, had to deal with the extraordinary weather events that forced closures throughout most of the United States," stated Bob Segersten, President of Solos Endoscopy, Inc. "Our next phase of growth is expected to be driven by market expansion into the European Union once we have completed the necessary certifications and obtain the CE Mark."
The Company expects to post its full unaudited financial results for the fiscal year ended December 31, 2010 on the OTC Markets Group website within in the next sixty days.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE Solos Endoscopy, Inc.